[Ip-health] ​Canadian Generic Pharmaceutical Association on US-Canada Trade Talks

James Love james.love at keionline.org
Wed Sep 5 10:50:50 PDT 2018

---------- Forwarded message ----------
From: Jody Cox
Date: Wed, Sep 5, 2018
Subject: CGPA Statement on the Resumption of US-Canada Trade Talks


For immediate release

CGPA Statement on the Resumption of US-Canada Trade Talks

Toronto, September 5, 2018 – The following is a statement by Jim Keon,
President of the

Canadian Generic Pharmaceutical Association (CGPA), on the resumption of
trade negotiations between the United States and Canada:

It is CGPA’s understanding that there are many US proposals on the table
that would require changes to Canadian law and delay competition from
generic and biosimilar medicines, including longer periods of data
protection for biologic drugs. Biologic medicines represent the fastest
growing cost segment of health care spending.

If such proposals were adopted they would create billions of dollars in new
costs for employers who sponsor employee drug benefit programs,
governments, and patients who pay for medicines out of pocket.

Canada’s intellectual property regime for pharmaceuticals was amended in
September 2017 as a result of the Comprehensive Economic and Trade
Agreement (CETA) with the European Union. The Parliamentary Budget Officer
has conservatively estimated that the two-year patent term extension
included in CETA will cost Canadians more $600 million annually.[1] It is
our understanding that the measures pursued by the US in the negotiations
go far beyond the measures included in CETA, and would be far more harmful
for Canadians if adopted.

The Government of Canada says it is committed to improving access to
necessary prescription medication and reducing the amounts Canadian
governments pay for these drugs.[2] As such, the Government of Canada must
not agree to NAFTA concessions that reduce access to essential medicines
and increase costs for those who pay for drugs.

Prime Minister Trudeau and Foreign Affairs Minister Freeland have stated
repeatedly that they will only sign an agreement that is in the best
interests of Canadians. Canada already has a strong intellectual property
regime for pharmaceuticals. There are no concessions in the area of
pharmaceutical intellectual property that are in the best interests of

About the Canadian Generic Pharmaceutical Association

The Canadian Generic Pharmaceutical Association (CGPA) represents Canada’s
generic pharmaceutical industry. The industry plays an important role in
controlling health-care costs in Canada. Generic drugs are dispensed to
fill more than 71 percent of all prescriptions but account for account for
only 21 percent of the $28-billion Canadians spend annually on prescription


For more information, please contact:

Jeff Connell
Vice President, Corporate Affairs
Canadian Generic Pharmaceutical Association (CGPA)
Tel: (416) 223-2333
Mobile: (647) 274-3379
Email: jeff at canadiangenerics.ca
Website: www.canadiangenerics.ca


[2] https://pm.gc.ca/eng/minister-health-mandate-letter

Jody Cox
Vice President, Federal and International Affairs
Canadian Generic Pharmaceutical Association (CGPA)
613-218-8839 | jody at canadiangenerics.ca

More information about the Ip-health mailing list